Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

Phase 2

Terminated

Conditions: Melanoma (Skin)
Kidney Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Biological: aldesleukin
Biological: anti-p53 T-cell receptor-transduced peripheral blood lymphocytes
Biological: autologous dendritic cell-adenovirus p53 vaccine
Biological: filgrastim
Drug: cyclophosphamide
Drug: fludarabine phosphate

First Posted Date: 2008-06-25

Last Posted Date: 2015-10-28

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 3

Registration Number: NCT00704938

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma

Phase 2

Terminated

Conditions: Neuroblastoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Natural Killer Cell Infusion
Drug: Mesna
Drug: Interleukin-2

First Posted Date: 2008-06-16

Last Posted Date: 2020-09-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00698009

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Phase 2

Completed

Conditions: Myelodysplastic/Myeloproliferative Neoplasms
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Chronic Myeloproliferative Disorders
Myelodysplastic Syndromes

Interventions: Biological: rituximab
Drug: busulfan
Drug: carmustine
Drug: cyclophosphamide
Drug: cytarabine
Drug: etoposide
Drug: fludarabine phosphate
Drug: melphalan
Radiation: total body irradiation (TBI)
Drug: anti-thymocyte globulin IV

First Posted Date: 2008-06-05

Last Posted Date: 2017-06-28

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 48

Registration Number: NCT00691015

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Total Marrow Irradiation for Refractory Acute Leukemia

Phase 1

Completed

Conditions: Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Multiple Myeloma

Interventions: Drug: cyclophosphamide
Drug: cyclosporine
Drug: Fludarabine
Drug: mycophenolate mofetil
Radiation: total marrow irradiation
Procedure: umbilical cord blood transplantation
Biological: Granulocyte colony-stimulating factor
Biological: HLA-matched related donor bone marrow

First Posted Date: 2008-05-30

Last Posted Date: 2017-12-05

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 12

Registration Number: NCT00686556

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)

Phase 1

Terminated

Conditions: Systemic Lupus Erythematosus
Systemic Sclerosis

Interventions: Procedure: Reduced Intensity Allogeneic Transplant
Drug: Fludarabine
Drug: Busulfan
Drug: Campath

First Posted Date: 2008-05-26

Last Posted Date: 2014-04-01

Lead Sponsor: New York Medical College

Target Recruit Count: 1

Registration Number: NCT00684255

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia
Lymphoid Leukemia
Chronic Myelogenous Leukemia
Malignant Lymphoma
Hodgkin's Disease
Chronic Lymphocytic Leukemia
Myeloproliferative Disorder
Anemia, Aplastic
Myelodysplastic Syndromes

Interventions: Drug: Fludarabine
Drug: Melphalan
Drug: Stem cells
Drug: Campath

First Posted Date: 2008-05-23

Last Posted Date: 2016-11-22

Lead Sponsor: University of Chicago

Target Recruit Count: 204

Registration Number: NCT00683046

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors

Phase 1

Conditions: Leukemia

Interventions: Drug: Busulfan
Drug: Fludarabine
Drug: Thymoglobulin
Radiation: Total Body Irradiation

First Posted Date: 2008-05-19

Last Posted Date: 2014-01-23

Lead Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago

Target Recruit Count: 30

Registration Number: NCT00679536

Locations: 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

Phase 2

Terminated

Conditions: Metastatic Renal Cell Cancer
Metastatic Cancer
Metastatic Melanoma

Interventions: Biological: Anti-NY ESO-1 T-cell receptor PBL
Drug: aldesleukin
Drug: Cyclophosphamide
Drug: fludarabine phosphate
Biological: ALVAC NY ESO-1 vaccine

First Posted Date: 2008-05-02

Last Posted Date: 2019-11-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT00670748

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma

Phase 1

Terminated

Conditions: Neuroblastoma

Interventions: Procedure: Related donor transplant
Procedure: Cord blood transplant
Drug: Busulfan
Drug: Thymoglobulin
Drug: Fludarabine

First Posted Date: 2008-05-01

Last Posted Date: 2016-06-24

Lead Sponsor: Columbia University

Target Recruit Count: 15

Registration Number: NCT00670410

Locations: 🇺🇸
Columbia Presbyterian Medical Center, Morgan Stanley Children's Hospital New York Presbyterian, New York, New York, United States

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

Phase 2

Terminated

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cavity Cancer

Interventions: Biological: Allopurinol
Drug: Cyclophosphamide
Drug: Fludarabine phosphate
Biological: Allogeneic natural killer cells
Radiation: total-body irradiation
Biological: Aldesleukin

First Posted Date: 2008-04-04

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 14

Registration Number: NCT00652899

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy